

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/183072 A1

(43) International Publication Date
01 September 2022 (01.09.2022)

(51) International Patent Classification:

C07K 14/145 (2006.01) C12N 15/867 (2006.01)

(21) International Application Number:

PCT/US2022/018027

(22) International Filing Date:

25 February 2022 (25.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/154,639 26 February 2021 (26.02.2021) US

(71) Applicant: **KELONIA THERAPEUTICS, INC.**
[US/US]; 5 Channel Center, Suite 501, Boston, MA 02210
(US).

(72) Inventors: **PERKINS, Molly R.**; 64 Bradlee Rd., Mil-
ton, Massachusetts 02186 (US). **FRIEDMAN, Kevin M.**;
4 Clover Circle, Melrose, Massachusetts 02176 (US).

(74) Agent: **SUN, Eileen, S.** et al.; Seed Intellectual Property
Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle,
Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: LYMPHOCYTE TARGETED LENTIVIRAL VECTORS

(57) Abstract: Provided herein are lentiviral vectors comprising a mutated, heterologous envelope protein, a targeting protein, and at least one transgene for delivery to and expression by a cell characterized by the targeting protein. Also provided are methods and materials for producing the lentiviral vectors described herein, methods for transducing target cells, and cells transduced by lentiviral vectors according to the present disclosure.



WO 2022/183072 A1